InVivo BioTech Services GmbH, based in Hennigsdorf, carries out applied research and development as well as the manufacturing and sale of products in the biotechnology sector. In the 2023 financial year the company reported sales revenues of EUR 8,912,709.28 and employed on average 86 persons. The company is a related entity of Bruker Daltonics Inc., Billerica/USA, and is included in the consolidated financial statements of Bruker Corporation. The company applies the disclosure reliefs for small corporations under the German Commercial Code and transferred the profit of EUR 1,498,077.52 to its shareholder under a profit and loss transfer agreement.
Die wirtschaftsnahe Forschung und Entwicklung, die Herstellung und der Vertrieb von Produkten im Bereich der Biotechnologie
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Neuruppin Local Court, HRB 5067 (as of 31 October 2026)
| Name | Type | City |
|---|---|---|
| Olaf Degen | Geschäftsführer(in) | Berlin |
| Jennifer Suhr | Geschäftsführer(in) | Berlin |
Source: German Commercial Register (Handelsregister) Neuruppin Local Court, HRB 5067 (as of 31 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2024 | €10,298,150 | €2,104,175 | €5,932,706 | 86 |
| 2023 | €8,912,709 | €1,498,222 | €5,893,638 | 86 |
| 2022 | €10,150,266 | €0 | €5,757,687 | 86 |
| 2021 | small company1 | €0 | €4,933,989 | 84 |
| 2020 | ≤ €12M1 | €0 | €6,785,976 | 63 |
| 2019 | small company1 | €0 | €5,968,188 | 58 |
| 2018 | ≤ €12M1 | €1,451,780 | €7,199,057 | 58 |
| 2017 | small company1 | €1,069,002 | €5,476,251 | 63 |
| 2016 | small company1 | €391,534 | €3,676,041 | — |
| 2015 | small company1 | €291,286 | €3,187,309 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
Sign in to download data
Source: German Commercial Register (Handelsregister) Neuruppin Local Court, HRB 5067 (as of 31 October 2026)
Silony Medical GmbH
Leinfelden-Echterdingen · Sonstige Forschung und Entwicklung im Bereich Natur-, Ingenieur-, Agrarwissenschaften und Medizin
regineering GmbH
Pollenfeld · Forschung und Entwicklung im Bereich Biotechnologie
Charles River Microbial Solutions Germany GmbH
Kaarst · Forschung und Entwicklung im Bereich Biotechnologie
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €5,069,675 | 74.2% |
| Material Costs | €1,437,122 | 21.0% |
| Depreciation | €292,954 | 4.3% |
| Interest & Similar | €28,172 | 0.4% |
